News

Net profit of Ajanta Pharma rose 18.40% to Rs 266.70 crore in the quarter ended March 2026 as against Rs 225.26 crore during the previous quarter ended March 2025. Sales rose 21.47% to Rs 1421.64 crore in the quarter ended March 2026 as against Rs 1170.41 crore during the previous quarter ended March 2025.For the full year,net profit rose 14.73% to Rs 1056.00 crore in the year ended March 2026 as against Rs 920.39 crore during the previous year ended March 2025. Sales rose 17.31% to Rs 5452.86 crore in the year ended March 2026 as against Rs 4648.10 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales1421.641170.41 21 5452.864648.10 17 OPM %23.4525.39 -25.5827.10 - PBDT392.48309.19 27 1550.791333.27 16 PBT347.11269.41 29 1377.651189.16 16 NP266.70225.26 18 1056.00920.39 15 Powered by Capital Market - Live News

Ajanta Pharma announced that the USFDA has concluded an inspection at its manufacturing facility at Paithan, in Maharashtra. The Inspection was conducted from 13 April 2026, to 21 April 2026, and closed with the issuance of Form-483 with 5 (five) observations.

Ajanta Pharma will hold a meeting of the Board of Directors of the Company on 5 May 2026.

Net profit of Ajanta Pharma rose 17.56% to Rs 273.77 crore in the quarter ended December 2025 as against Rs 232.88 crore during the previous quarter ended December 2024. Sales rose 19.95% to Rs 1374.84 crore in the quarter ended December 2025 as against Rs 1146.13 crore during the previous quarter ended December 2024. ParticularsQuarter EndedDec. 2025Dec. 2024% Var. Sales1374.841146.13 20 OPM %27.8027.99 - PBDT402.11343.36 17 PBT358.60307.39 17 NP273.77232.88 18 Powered by Capital Market - Live News

Ajanta Pharma will hold a meeting of the Board of Directors of the Company on 30 January 2026.Powered by Capital Market - Live News